A POLYMER TRITON X-100 CONJUGATE CAPABLE OF PH-DEPENDENT RED-BLOOD-CELL LYSIS - A MODEL SYSTEM ILLUSTRATING THE POSSIBILITY OF DRUG-DELIVERY WITHIN ACIDIC INTRACELLULAR COMPARTMENTS

被引:40
作者
DUNCAN, R
FERRUTI, P
SGOURAS, D
TUBOKUMETZGER, A
RANUCCI, E
BIGNOTTI, F
机构
[1] UNIV KEELE,DEPT BIOL SCI,CRC,POLYMER DRUG DELIVERY RES GRP,KEELE ST5 5BG,STAFFS,ENGLAND
[2] UNIV BRESCIA,DIPARTIMENTO CHIM & FIS MAT,I-25000 BRESCIA,ITALY
关键词
PH-DEPENDENT DELIVERY; POLY(AMIDO AMINES); TARGETING; DRUG DELIVERY;
D O I
10.3109/10611869409015915
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poly(amidoamines) are soluble polymers containing tertiary amino and amido groups regularly arranged along the macromolecular chain, and their net average charge alters considerably as pH changes from neutral to acidic leading to a change in conformation. This property provides the possi bility to design polymer-drug conjugates that are, following intravenous administration, relatively compacted and thus protect a drug payload in the circulation, but following pinocytic internalisation into acidic intracellular compartments unfold permitting pH-triggered intracellular drug delivery. To study the feasibility of this approach, a covalent conjugate of a poly(amidoamine) (MBI) was prepared to contain the membrane lytic non-ionic detergent Triton X-100 (as a model), and its ability to lyse red blood cells in vitro was used as an indicator of conjugate conformation at different pHs. Although Triton X-100 was highly lytic at pH 5.5, 7.4 and 8.0, and the parent polymer MBI was not lytic under any conditions, the conjugate only showed concentration-dependent red blood cell lysis at pH 5.5. Moreover, incubation of human leukaemic cells (CCRF) with these substrates showed conjugate to be more toxic than MBI (IC50 values of 100 mu g/ml and 650 mu g/ml respectively) and less toxic than Triton X-100 (IC50 of 1 mu g/ml).
引用
收藏
页码:341 / 347
页数:7
相关论文
共 19 条
[1]  
BHAKOO M, 1985, CAN J BIOCHEM CELL B, V63, P1
[2]  
BIGNOTTI F, 1994, IN PRESS MACROMOLECU
[3]  
CHU BCF, 1981, J PHARMACOL EXP THER, V219, P389
[4]   INHIBITION OF LEUKEMIA-CELL PROLIFERATION BY FOLIC-ACID POLYLYSINE-MEDIATED INTRODUCTION OF C-MYB ANTISENSE OLIGODEOXYNUCLEOTIDES INTO HL-60 CELLS [J].
CITRO, G ;
SZCZYLIK, C ;
GINOBBI, P ;
ZUPI, G ;
CALABRETTA, B .
BRITISH JOURNAL OF CANCER, 1994, 69 (03) :463-467
[5]   DRUG POLYMER CONJUGATES - POTENTIAL FOR IMPROVED CHEMOTHERAPY [J].
DUNCAN, R .
ANTI-CANCER DRUGS, 1992, 3 (03) :175-210
[6]   PRECLINICAL EVALUATION OF POLYMER-BOUND DOXORUBICIN [J].
DUNCAN, R ;
SEYMOUR, LW ;
OHARE, KB ;
FLANAGAN, PA ;
WEDGE, S ;
HUME, IC ;
ULBRICH, K ;
STROHALM, J ;
SUBR, V ;
SPREAFICO, F ;
GRANDI, M ;
RIPAMONTI, M ;
FARAO, M ;
SUARATO, A .
JOURNAL OF CONTROLLED RELEASE, 1992, 19 (1-3) :331-346
[7]  
DUNCAN R, 1994, IN PRESS CLIN PHARMA
[8]   SYNTHESIS, PHYSICOCHEMICAL PROPERTIES AND BIOMEDICAL APPLICATIONS OF POLY(AMIDO-AMINE)S [J].
FERRUTI, P ;
MARCHISIO, MA ;
BARBUCCI, R .
POLYMER, 1985, 26 (09) :1336-1348
[9]  
FERRUTI P, 1984, ADV POLYM SCI, V58, P55
[10]  
FERRUTI P, 1990, Patent No. 90160714